Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.

ABSTRACT:

Objective

The optimal treatment for vitreoretinal lymphoma (VRL) remains a challenge, as central nervous system (CNS) relapse occurs frequently, leading to the worst impact on survival. We previously proposed combined intravitreal methotrexate and systemic high-dose methotrexate therapy for this disease. This study aimed to report the long-term outcomes of patients with VRL using this combination treatment.

Methods

We conducted a retrospective cohort study on patients with VRL at a tertiary referral center between 2003 and 2018.

Results

Thirty-two patients were included, of whom 23 had primary VRL (PVRL) and nine had concurrent intraocular and CNS diseases. The treatment was well tolerated. Twenty-six (81.3%) patients achieved complete response (CR). After a median fo

SUBMITTER: Cheng CL 

PROVIDER: S-EPMC10134364 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature